Brain Cancer Trial, Recruiting NCT04833335 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT04833335
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have cancer that has spread to the brain (brain metastases), where the original cancer has been confirmed by laboratory testing of tumour tissue
  • People who have received Gamma Knife (a type of targeted radiation treatment) within the last 4 months before joining the trial
  • People who have a brain lesion that is suspected of either growing again or developing a complication called radionecrosis (tissue damage from radiation), meaning the lesion has grown by 25% or more in size
  • People who have a lesion measuring at least 1 cm in the area that shows up when a contrast dye called gadolinium is used during a brain scan

Who may not be able to join:

  • People who are pregnant
  • People who have a history of a brain tumour that started in the brain (rather than spreading from elsewhere in the body)
  • People who are unable to have an MRI scan, or who have a history of allergic reaction to contrast dye used in scans
  • People who experience claustrophobia (fear of enclosed spaces, such as an MRI machine)
  • People who are not able to give their own informed consent to participate
  • People who have epilepsy or have recently had a stroke
  • People who are currently participating in another clinical research study
  • People who do not have health care insurance

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +330661884335

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
24 January 2023
Est. completion
24 September 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Diagnostic performance of ASL quantitative analysis in brain metastasis following GK treatment : tumor perfusion with quantitative measurement (one value) of RCBF (relative cerebral blood flow) on the ASL sequence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov